Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 13.1% - Here's What Happened

Key Points

• Iovance Biotherapeutics shares fell 13.1% to about $8.31 after updated lung-cancer trial data prompted concerns about the modest 24.6% overall response rate and the limited 11.4% response rate in KRAS-mutant disease.
• The data showed stronger results in selected groups, including a 43.3% response rate for KRAS wild-type patients and 59.1% in a biomarker-enriched subgroup. Iovance plans to pursue a supplemental approval application in 2027 and begin a registrational-intent study in November.
• Analysts remain broadly positive, with a “Moderate Buy” consensus and an average price target of $13.20, while the company’s latest quarter showed revenue growth of 65.7% and better-than-expected earnings despite continued net losses.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) fell 13.1% on Friday. The company traded as low as $8.38 and last traded at $8.3110. Approximately 5,355,585 shares were traded during mid-day trading, a decline of 66% from the average session volume of 15,649,962 shares. The stock had previously closed at $9.56.

More Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reported a 24.6% objective response rate among 69 patients with previously treated non-squamous mNSCLC. The KRAS wild-type subgroup posted a 43.3% response rate, while a novel biomarker-enriched subgroup reached 59.1%, supporting a precision-medicine approach. Iovance Reports Updated IOV-LUN-202 Results
• Positive Sentiment: Cohorts 1 and 2 are completing enrollment and are expected to support a supplemental Biologics License Application for lifileucel in non-squamous mNSCLC in 2027. Iovance also plans to begin enrollment in November for POSITILITY, a biomarker-enriched study with registrational intent. Iovance Lung Cancer Trial Update
• Positive Sentiment: Earlier melanoma and sarcoma findings reinforced investor interest in lifileucel’s potential beyond its current advanced-melanoma indication, including a reported 50% response rate in refractory undifferentiated pleomorphic sarcoma and liposarcoma. Lifileucel Shows 50% Response Rate
• Neutral Sentiment: Unusually heavy call-option buying and expectations for an earnings beat reflected speculative optimism, but these signals do not establish durable demand or clinical success. Iovance Earnings Expectations
• Negative Sentiment: The market reaction turned sharply negative after the updated lung-cancer readout. Investors appeared concerned that the 24.6% overall response rate was less compelling than the biomarker-selected results and that the 11.4% response rate in KRAS-mutant disease limits the addressable population, increasing regulatory and execution risk. Iovance Stock Reaction to Updated Lung Cancer Data

Analysts Set New Price Targets

Several research analysts recently commented on IOVA shares. Mizuho lifted their target price on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an "outperform" rating in a report on Tuesday, August 18th. Citizens Jmp boosted their price objective on Iovance Biotherapeutics from $5.00 to $8.00 and gave the company a "market outperform" rating in a research report on Friday, August 7th. Robert W. Baird increased their price objective on shares of Iovance Biotherapeutics from $6.00 to $11.00 and gave the company a "neutral" rating in a research note on Thursday, October 8th. Wells Fargo & Company raised their target price on Iovance Biotherapeutics from $14.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 30th. Finally, HC Wainwright increased their target price on shares of Iovance Biotherapeutics from $9.00 to $20.00 and gave the stock a "buy" rating in a research report on Tuesday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Iovance Biotherapeutics currently has an average rating of "Moderate Buy" and an average price target of $13.20.

Iovance Biotherapeutics Stock Down 10.0%

The stock has a market cap of $3.90 billion, a P/E ratio of -11.69 and a beta of 0.76. The stock has a fifty day simple moving average of $11.38 and a 200-day simple moving average of $5.79.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.02. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.51%. The firm had revenue of $99.31 million during the quarter, compared to analyst estimates of $87.83 million. During the same period in the prior year, the business earned ($0.33) EPS. The company's revenue for the quarter was up 65.7% compared to the same quarter last year. Sell-side analysts anticipate that Iovance Biotherapeutics, Inc. will post -0.45 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in IOVA. BlackRock Inc. bought a new position in Iovance Biotherapeutics during the second quarter worth about $153,744,000. Palo Alto Investors LP acquired a new position in Iovance Biotherapeutics in the second quarter valued at about $22,032,229. Bank of America Corp DE acquired a new stake in Iovance Biotherapeutics during the second quarter worth about $20,773,000. Knott David M Jr bought a new stake in shares of Iovance Biotherapeutics during the 1st quarter worth approximately $5,616,000. Finally, Rice Hall James & Associates LLC acquired a new position in Iovance Biotherapeutics during the second quarter valued at approximately $6,406,000. Institutional investors and hedge funds own 77.03% of the company's stock.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc NASDAQ: IOVA is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient's tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company's lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.